Key Points
- Insider Joana Goncalves sold 7,000 shares on Jan 15 at an average price of $31.81 for $222,670, leaving her with 1,518 shares — an 82.18% decrease in her direct ownership; she also sold 7,000 shares on Dec 19 at about $30.61.
- Oruka Therapeutics is a clinical‑stage biopharma (lead candidate ONCT‑01 in Phase 1) with a market cap of $1.62 billion and recent trading near its 52‑week high (~$33.40); analysts show a consensus “Moderate Buy” rating with an average price target of $50.67, though opinions range from sell to high buy/overweight estimates.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total value of $222,670.00. Following the sale, the insider directly owned 1,518 shares in the company, valued at $48,287.58. This trade represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Joana Goncalves also recently made the following trade(s):
- On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00.
Oruka Therapeutics Stock Performance
Shares of ORKA opened at $33.40 on Friday. The stock has a market capitalization of $1.62 billion, a PE ratio of -17.58 and a beta of -0.39. The company's fifty day moving average is $29.60 and its 200 day moving average is $22.04. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $33.85.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. As a group, research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on ORKA shares. Barclays assumed coverage on Oruka Therapeutics in a research note on Monday, October 13th. They set an "overweight" rating and a $48.00 price objective on the stock. Piper Sandler assumed coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an "overweight" rating and a $75.00 target price for the company. UBS Group initiated coverage on Oruka Therapeutics in a report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Finally, BTIG Research lifted their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $50.67.
View Our Latest Report on ORKA
Hedge Funds Weigh In On Oruka Therapeutics
A number of large investors have recently bought and sold shares of ORKA. Legal & General Group Plc bought a new position in Oruka Therapeutics in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Oruka Therapeutics during the second quarter valued at $31,000. BNP Paribas Financial Markets boosted its stake in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after purchasing an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics in the third quarter worth about $39,000. Finally, Russell Investments Group Ltd. purchased a new position in Oruka Therapeutics in the 3rd quarter worth about $43,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
